Ann Waldo, Daniel Barth-Jones, Fielding Greaves
The “Join Session” button will become active on the day of the conference.
Evolving state law is undermining the legal foundation governing medical research. Because CCPA neither exempts all federally permissible medical research nor recognizes HIPAA de-identification, medical research will face significant new legal complexities and delays. Efforts are underway to protect research. The California Senate Health Committee has advanced a bill to take medical research and HIPAA-de-identified health data out of the CCPA, and similar efforts continue in other states. This session will explain current research uses of HIPAA de-identified data, review CCPA de-identification and research provisions, analyze technical and practical differences between HIPAA, CCPA, and FTC-based de-identification standards, and describe 2020 legislative efforts to minimize harm to medical research from CCPA and other new laws.
Ann Waldo, Principal, Waldo Law Offices
Daniel Barth-Jones, Professor, Mailman School of Public Health, Columbia University
Fielding Greaves, Senior Director, State & Regional Government Affairs, AdvaMed
Readings:
